Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (39)
Mathew W. MacCumber, Justin S. Yu, Alexandros Sagkriotis, Guruprasad B, Bhavya Burugapalli, Xiaoyu Bi, Neetu Agashivala & Charles C. Wykoff. (2023) Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Canadian Journal of Ophthalmology 58:3, pages 252-261.
Crossref
Crossref
Ursula Schmidt-Erfurth, Zufar Mulyukov, Bianca S. Gerendas, Gregor S. Reiter, Daniel Lorand, Georges Weissgerber & Hrvoje Bogunović. (2022) Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye 37:6, pages 1160-1169.
Crossref
Crossref
Levon M. Khachigian, Gerald Liew, Kelvin Y. C. Teo, Tien Y. Wong & Paul Mitchell. (2023) Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. Journal of Translational Medicine 21:1.
Crossref
Crossref
Ching-Yao Tsai, Chien-Liang Wu, Cheng-Kuo Cheng, Yun-Dun Shen, Wen-Chuan Wu, Pei-Chang Wu, Arslan Tsai & Jiann-Torng Chen. (2023) Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis. BMC Ophthalmology 23:1.
Crossref
Crossref
Arshad M. Khanani, David M. Brown, Glenn J. Jaffe, Charles C. Wykoff, Eser Adiguzel, Randall Wong, Xiangyi Meng & Jeffrey S. Heier. (2022) MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology 129:9, pages 974-985.
Crossref
Crossref
Alexandros Rouvas, Ioannis Datseris, Sofia Androudi, Miltiadis Tsilimbaris, Stamatina A Kabanarou, Nikolaos Pharmakakis, Chryssanthi Koutsandrea, Alexander Charonis, Olga Kousidou & Georgia Pantelopoulou. (2022) A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The “ELEVATE” Study. Clinical Ophthalmology Volume 16, pages 2579-2593.
Crossref
Crossref
Juan Camilo Suárez Escudero, María del Pilar Oviedo Cáceres, Yuliana Llano Naranjo, Johana Arias Uribe, José Daniel Villegas Mesa, María Camila Zapata Vásquez, Jorge Luis Ferreira Morales, Jessica Tatiana Reyes Cisneros, Karen Cano Calle, Sydney Goldfeder de Gracia, Juan Felipe González Franco & Esau Astudillo Valverde. (2022) Etiología de baja visión y ceguera en siete centros de referencia en Colombia entre los años 2012 a 2017. Revista Cuidarte.
Crossref
Crossref
Ashwin Gupta, Nicholas Nosbisch, Ishan Agarwal, Anjali Patel, Sowmyanarayanan Thuppal, Chaitanya Mamillipalli, Jessi Prentice, Jaycob Avaylon, Ron Gallemore & Ramanath Bhandari. (2022) Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Re:GEN Open 2:1, pages 4-8.
Crossref
Crossref
Ling Yeung, Yi-Ting Hsieh, Chang-Hao Yang, Lee-Jen Chen, Shih-Jen Chen, Cheng-Kuo Cheng, Shwu-Jiuan Sheu, Ching-Yao Tsai, Tsung-Tien Wu, Wei-Chi Wu & San-Ni Chen. (2021) Management of neovascular age-related macular degeneration: Taiwan expert consensus. Journal of the Formosan Medical Association 120:12, pages 2061-2071.
Crossref
Crossref
Josh O. Wallsh & Ron P. Gallemore. (2021) Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. Cells 10:5, pages 1049.
Crossref
Crossref
Mohamed A. Hamid, Nizar S. Abdelfattah, Jamshid Salamzadeh, Sahar T. A. Abdelaziz, Ahmed M. Sabry, Khaled M. Mourad, Azza A. Shehab & Baruch D. Kuppermann. (2021) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. International Journal of Retina and Vitreous 7:1.
Crossref
Crossref
Sanna Koponen, Emmi Kokki, Kati Kinnunen & Seppo Ylä-Herttuala. (2021) Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye. Pharmaceutics 13:2, pages 219.
Crossref
Crossref
E Ertan, N Efe, MC Sabaner & M Dogan. (2021) Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study. Nigerian Journal of Clinical Practice 24:12, pages 1824.
Crossref
Crossref
Yuma Tsunekawa, Keiko Kataoka, Keiko Asai, Yasuki Ito & Hiroko Terasaki. (2020) Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. Japanese Journal of Ophthalmology 65:1, pages 69-76.
Crossref
Crossref
Michael Karampelas, Panagiotis Malamos, Petros Petrou, Ilias Georgalas, Dimitrios Papaconstantinou & Dimitrios Brouzas. (2020) Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration. Ophthalmology and Therapy 9:4, pages 739-756.
Crossref
Crossref
Federico Ricci, Francesco Bandello, Pierluigi Navarra, Giovanni Staurenghi, Michael Stumpp & Marco Zarbin. (2020) Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences 21:21, pages 8242.
Crossref
Crossref
Zongyi Wang, Mengyang Li, Yuou Yao, Jie Hu, Jiyang Tang, Ran Tang, Zhenyu Piao & Jinfeng Qu. (2020) Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology 2020, pages 1-9.
Crossref
Crossref
Jordi Monés & Marc Biarnés. (2019) Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. European Journal of Ophthalmology 30:5, pages 1082-1090.
Crossref
Crossref
David T. Wong, George N. Lambrou, Anat Loewenstein, Ian Pearce & Annabelle A. Okada. (2020) SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina 40:6, pages 1010-1020.
Crossref
Crossref
Nazanin Ebrahimiadib, Alireza Lashay, Hamid Riazi-Esfahani, Sepideh Jamali, Alireza Khodabandeh, Mohammad Zarei, Ramak Roohipoor, Hassan Khojasteh, Fatemeh Bazvand, Mina Ojani, Mojtaba Shahabinejad, Mehdi Yaseri, Bobeck S. Modjtahedi, Samaneh Davoudi & Mohammad Riazi-Esfahani. (2020) Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab. Ophthalmic Surgery, Lasers and Imaging Retina 51:3, pages 145-151.
Crossref
Crossref
Pravin U. Dugel, David S. Boyer, Andrew N. Antoszyk, Nathan C. Steinle, Michael P. Varenhorst, Joel A. Pearlman, Mark C. Gillies, Robert P. Finger, Megan E. Baldwin & Ian M. Leitch. (2020) Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina 4:3, pages 250-263.
Crossref
Crossref
Darina Aleksandrovna Konovalova. (2020) EXPERIENCE OF AFLIBERCEPT APPLICATION IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION. International Medical Journal:4(100), pages 90-96.
Crossref
Crossref
Anniken Burés Jelstrup, Esther Pomares & Rafael Navarro. (2020) Relationship between Aflibercept Efficacy and Genetic Variants of Genes Associated with Neovascular Age-Related Macular Degeneration: The BIOIMAGE Trial. Ophthalmologica 243:6, pages 461-470.
Crossref
Crossref
Kimberly Spooner, Samantha Fraser‐Bell, Thomas Hong & Andrew Chang. (2019) Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long‐term treatment with bevacizumab or ranibizumab. Clinical & Experimental Ophthalmology 48:1, pages 53-60.
Crossref
Crossref
Kimberly Spooner, Thomas Hong, Rashmi Nair, Nicholas Chian Chiang Chow, Geoffrey K. Broadhead, Wijeyanthy Wijeyakumar & Andrew A. Chang. (2019) Long‐term outcomes of switching to aflibercept for treatment‐resistant neovascular age‐related macular degeneration. Acta Ophthalmologica 97:5.
Crossref
Crossref
Zois Papadopoulos. (2019) Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. European Journal of Ophthalmology 29:4, pages 368-378.
Crossref
Crossref
Marco Zarbin, Min Tsuboi, Lauren F. Hill & Ivaylo Stoilov. (2019) Simulating an Anti–Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration. Ophthalmology 126:6, pages 849-855.
Crossref
Crossref
Allison Low, Ambar Faridi, Kavita V Bhavsar, Glenn C Cockerham, Michele Freeman, Rochelle Fu, Robin Paynter, Karli Kondo & Devan Kansagara. (2019) Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. British Journal of Ophthalmology 103:4, pages 442-451.
Crossref
Crossref
Richard P. Gale, Sajjad Mahmood, Helen Devonport, Praveen J. Patel, Adam H. Ross, Gavin Walters, Louise Downey, Samer El-Sherbiny, Mary Freeman, Simon Berry & Nitin Jain. (2019) Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye 33:S1, pages 1-21.
Crossref
Crossref
Kimberly Spooner, Thomas Hong, Bobak Bahrami & Andrew Chang. (2019) A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Acta Ophthalmologica 97:1, pages 15-23.
Crossref
Crossref
Usha Chakravarthy, Vladimir Bezlyak, Alexandros Sagkriotis, Ray Griner, Adrian Skelly, David S. Boyer & Fran Milnes. (2019) Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence. Ophthalmology Retina 3:1, pages 8-15.e1.
Crossref
Crossref
Flora Elwes, Shyamanga Borooah, Peter Aspinall, Peng Yong Sim, Cheng Yi Loo, Ana-Maria Armbrecht, Baljean Dhillon & Peter Cackett. (2018) Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. BMC Ophthalmology 18:1.
Crossref
Crossref
Yvonne Nowosielski, Gertrud Haas, Christof Seifarth, Werner Wohlfarter, Ramon Tasan, Michael Verius, Josef Troger & Nikolaos Bechrakis. (2018) The involvement of NK1 and Y2 receptor in the development of laser-induced CNVs in C57Bl/6N mice. Experimental Eye Research 177, pages 87-95.
Crossref
Crossref
Emilia Maggio, Mauro Sartore, Marcella Attanasio, Giorgia Maraone, Massimo Guerriero, Antonio Polito & Grazia Pertile. (2018) Anti–Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. American Journal of Ophthalmology 195, pages 209-222.
Crossref
Crossref
Clare F. McCloskey, Ann-Marie Mongan, Shivona Chetty, Darren M. J. McAteer & Shauna M. Quinn. (2018) Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study. Ophthalmology and Therapy 7:1, pages 173-183.
Crossref
Crossref
Samhitha Gudla, Divya Tenneti, Makrand Pande & Srinivas M. Tipparaju. 2018. Drug Delivery for the Retina and Posterior Segment Disease. Drug Delivery for the Retina and Posterior Segment Disease
83
94
.
Dae Joong Ma & Hyeong Gon Yu. (2017) Refractory Neovascular Age-related Macular Degeneration. Journal of Retina 2:2, pages 51-59.
Crossref
Crossref
. (2017) The VEGF Treatment of AMD Switch Study (The vTAS Study). Asia-Pacific Journal of Ophthalmology.
Crossref
Crossref
Pedro Neves Cardoso, Ana Fernanda Pinheiro, Jorge Meira, Ana Catarina Pedrosa, Manuel S. Falcão, João Pinheiro-Costa, Fernando Falcão-Reis & Ângela M. Carneiro. (2017) Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results. Journal of Ophthalmology 2017, pages 1-6.
Crossref
Crossref